P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy as 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)

S. Ren; G. Gao; W. Li; X. Chen; F. Wu; C. Su; J. Zhao; Y. Sun; W. Cai; C. Zhou

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy as 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)

【24h】

P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy as 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)

机译：NAB-PACLITAXEL单疗法的安全性和有效性和疗效在PTS中为2ND或后来的线路设置，具有广泛的SCLC，单级单臂研究（NCT02262897）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 》 |2017年第11期| 共1页
作者
S. Ren; G. Gao; W. Li; X. Chen; F. Wu; C. Su; J. Zhao; Y. Sun; W. Cai; C. Zhou;
展开▼
作者单位

Oncology Shanghai Pulmonary Hospital Tongji University School of Medicine Tongji University;

Oncology Shanghai Pulmonary Hospital Tongji University School of Medicine Tongji University;

Department of Medical Oncology Shanghai Pulmonary Hospital Tongji University School of Medicine;

Department of Medical Oncology Shanghai Pulmonary Hospital Tongji University School of Medicine;

Medical Oncology Shanghai Pulmonary Hospital;

Shanghai Pulmonary Hospital Tongji University School of Medicine;

Shanghai Pulmonary Hospital Tongji University School of Medicine;

Oncology Shanghai Pulmonary Hospital Tongji University School of Medicine Tongji University;

Medical Oncology Shanghai Pulmonary Hospital;

Medical Oncology Shanghai Pulmonary Hospital Tongji University;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy as 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897) [J] . S. Ren, G. Gao, W. Li, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017 ,第11期

机译：NAB-PACLITAXEL单疗法的安全性和有效性和疗效在PTS中为2ND或后来的线路设置，具有广泛的SCLC，单级单臂研究（NCT02262897）
2. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. [J] . ODay SJ, Maio M, Chiarion Sileni V, Annals of oncology: official journal of the European Society for Medical Oncology . 2010 ,第8期

机译：ipilimumab单一疗法对已治疗的晚期黑色素瘤患者的疗效和安全性：一项多中心单臂II期研究。
3. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phasen II study [J] . J. D. Wolchok Annals of Oncology . 2010 ,第8期

机译：ipilimumab单一疗法对晚期晚期黑色素瘤患者的疗效和安全性：多中心单臂II期临床研究
4. IMANI-1 TC3WP Single Drug HAART -Proof of Concept Study Pilot Study of the Safety and Efficacy of Kaletra (LPV/r) as Single Drug HAART in HIV+ ARV- Naive Patients - Interim Analysis of Subjects Completing Final 48 Week Data [C] . J.C. Gathe Jr., M. Washington, C. Mayberry International AIDS Conference . 2004

机译：Imani-1 TC3WP单药搭载概念研究试验试验研究Kaletra（LPV / R）作为艾滋病毒+ ARV天真患者单药HAART的安全性和有效性 - 临时分析受试者完成最终的48周数据
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer [O] . Yasuhiro Kato, Yusuke Okuma, Kageaki Watanabe, -1

机译：在先前的晚期非小细胞肺癌化疗标准后每周进行纳米粒子白蛋白结合的紫杉醇（nab-紫杉醇）单药治疗的单臂II期试验
7. 521TiP IMpower133: A phase I/III study of atezolizumab (atezo) with carboplatin (carbo) and etoposide as 1L therapy in patients (pts) with extensive-stage SCLC (ES-SCLC) [O] . T.S.K. Mok, L. Horn, M. Reck, 2016

机译：521tip offower133：具有Carboplatin（Carbo）和依托皂苷的atezolizumab（Atezo）的一期I / III研究，患者（PTS）具有广泛的SCLC（ES-SCLC）

P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy as 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)

著录项

相似文献

相关主题

期刊订阅